275 related articles for article (PubMed ID: 31959914)
1. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.
Tan M; Mosaoa R; Graham GT; Kasprzyk-Pawelec A; Gadre S; Parasido E; Catalina-Rodriguez O; Foley P; Giaccone G; Cheema A; Kallakury B; Albanese C; Yi C; Avantaggiati ML
Cell Death Differ; 2020 Jul; 27(7):2143-2157. PubMed ID: 31959914
[TBL] [Abstract][Full Text] [Related]
2. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver.
Fletcher JA; Deja S; Satapati S; Fu X; Burgess SC; Browning JD
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31012869
[TBL] [Abstract][Full Text] [Related]
3. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
4. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
[TBL] [Abstract][Full Text] [Related]
5. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
[TBL] [Abstract][Full Text] [Related]
6. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
7. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
10. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
11. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
12. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
13. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
14. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
[TBL] [Abstract][Full Text] [Related]
15. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
16. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
[TBL] [Abstract][Full Text] [Related]
17. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
[TBL] [Abstract][Full Text] [Related]
18. Mice lacking
Gallo-Ebert C; Francisco J; Liu HY; Draper R; Modi K; Hayward MD; Jones BK; Buiakova O; McDonough V; Nickels JT
J Biol Chem; 2018 Apr; 293(16):5956-5974. PubMed ID: 29491146
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
20. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
